WARF Therapeutics


Jump to section:

WARF Therapeutics Drug Discovery Seminar Series

WARF Therapeutics is proud to partner with several departments to offer seminar series events to bring in national experts who will share their translational drug discovery experience with campus.

If you are interested in drug discovery, please join us at any of these events.


Noon – 1 p.m. | Waisman Center
Featured Speaker Kapil Bharti, PhD, Senior Investigator leading the Ocular and Stem Cell Translational Research Unit, National Eye Institute. Bharti will share how his lab focuses on developing in vitro disease models, setting up high throughput drug screens and developing cell-based therapy for retinal degenerative diseases.


Noon – 1 p.m. | Waisman Center
Craig Erickson, MD, Cincinnati Children’s Hospital. Dr. Erickson’s group carries out preclinical and clinical research to develop new targeted drug treatments in developmental disabilities (autism spectrum disorders, Fragile X syndrome, and Angelman syndrome). He is a leading expert in conducting clinical trials in individuals with Fragile X. 

10:30 – 11:30 a.m. | McArdle Laboratory for Cancer Research | 1345 HSLC
Featured Speaker Goutham Narla, MD, Ph.D.

Seminar Title: Drugging the undruggable: lessons from DNA tumor viruses, cancer mutations, and small molecules
Dr. Narla earned his BS in Biology and Economics from Santa Clara University in California and his MD, PhD, and performed his residency at Mount Sinai School of Medicine in New York. He moved to Ohio in 2012 to work at Case Western Reserve University (CWRU) and in July 2018, he joined the faculty at Michigan Medicine to become the seventh Chief of the Division of Genetic Medicine.

10:30 – 11:30 a.m. | McArdle Laboratory for Cancer Research | 1345 HSLC
Featured Speaker Robert Yarchoan, MD

Seminar Title: The Spectrum of KSHV-associated Diseases: Pathogenesis and Insights for Therapy
Dr. Robert Yarchoan received his B.A. from Amherst College and his M.D. from the University of Pennsylvania. He joined the laboratory of Dr. Samuel Broder, where he played a major role in the development of the first effective therapies for HIV infection, including zidovudine (AZT), didanosine (ddI), and zalcitabine (ddC). His current research interests are focused on AIDS-related malignancies, especially tumors caused by Kaposi's sarcoma-associated herpesvirus (KSHV).